CRM-Hib vaccine conjugate (Novartis/GlaxoSmithKline)

N/A

Report date: 2023/04/20 18:00:27

Base Information

Drug NameCRM-Hib vaccine conjugate (Novartis/GlaxoSmithKline)
Drug Alias NamePRP-CRM197 conjugate Hib vaccine维可思Hib-CRM197 vaccine conjugateMonovalent Hib vaccineVaxem Hib +[6] 
ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHaemophilus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesGlaxosmithkline PlcNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd
Inactive CompaniesNovartis Vaccine And Diagnostic Reagents Co LtdNovartis VaccinesShanghai Novartis Trading Ltd
Active IndicationsHaemophilus Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ07AG01
Related LinksN/A